Headlands Technologies LLC Sells 1,464 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Headlands Technologies LLC reduced its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR) by 35.6% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 2,647 shares of the biotechnology company’s stock after selling 1,464 shares during the quarter. Headlands Technologies LLC’s holdings in United Therapeutics were worth $934,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the business. Signaturefd LLC increased its position in United Therapeutics by 4.7% during the 4th quarter. Signaturefd LLC now owns 663 shares of the biotechnology company’s stock worth $234,000 after purchasing an additional 30 shares in the last quarter. Parallel Advisors LLC grew its stake in shares of United Therapeutics by 2.8% during the fourth quarter. Parallel Advisors LLC now owns 1,090 shares of the biotechnology company’s stock worth $385,000 after buying an additional 30 shares during the last quarter. Great Lakes Advisors LLC increased its holdings in shares of United Therapeutics by 1.6% during the fourth quarter. Great Lakes Advisors LLC now owns 1,974 shares of the biotechnology company’s stock worth $697,000 after buying an additional 31 shares in the last quarter. Oregon Public Employees Retirement Fund boosted its holdings in shares of United Therapeutics by 0.4% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 9,108 shares of the biotechnology company’s stock valued at $3,214,000 after acquiring an additional 33 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC grew its position in United Therapeutics by 0.8% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 4,913 shares of the biotechnology company’s stock worth $1,761,000 after acquiring an additional 39 shares during the last quarter. 94.08% of the stock is owned by institutional investors and hedge funds.

United Therapeutics Trading Up 1.8 %

NASDAQ:UTHR opened at $312.26 on Thursday. The firm has a fifty day simple moving average of $336.64 and a two-hundred day simple moving average of $355.09. United Therapeutics Co. has a 12 month low of $227.75 and a 12 month high of $417.82. The stock has a market capitalization of $14.02 billion, a price-to-earnings ratio of 13.71, a PEG ratio of 0.97 and a beta of 0.64.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.10 by $0.09. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The business had revenue of $735.90 million during the quarter, compared to the consensus estimate of $734.74 million. During the same quarter last year, the firm posted $4.36 EPS. Equities analysts predict that United Therapeutics Co. will post 24.48 earnings per share for the current fiscal year.

Insider Activity

In other United Therapeutics news, Director Tommy G. Thompson sold 2,500 shares of United Therapeutics stock in a transaction that occurred on Monday, March 24th. The shares were sold at an average price of $318.80, for a total transaction of $797,000.00. Following the transaction, the director now owns 8,480 shares of the company’s stock, valued at $2,703,424. This trade represents a 22.77 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Michael Benkowitz sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $371.05, for a total value of $3,710,500.00. Following the completion of the transaction, the chief operating officer now owns 2,577 shares in the company, valued at $956,195.85. The trade was a 79.51 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 72,500 shares of company stock worth $26,134,500 over the last 90 days. 11.90% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the stock. HC Wainwright reissued a “buy” rating and set a $425.00 target price on shares of United Therapeutics in a report on Thursday, February 27th. StockNews.com downgraded United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, February 27th. Finally, UBS Group lifted their target price on United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a report on Wednesday, January 8th. One analyst has rated the stock with a sell rating, two have issued a hold rating and ten have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $388.25.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.